Aeolian Advisors’ investment strategy includes the objective of offering very specific opportunities iamong the small and emerging growth biopharmaceutical and medical device companies balancing the very high risk associated with such investments with the opportunity for long term higher than average returnst.

The focus is on companies that are undervalued by our estimates; have strong scientific and business leadership; secured intellectual property that enables them freedom to operate; novel products or technology in areas of high unmet medical need, and a clear regulatory pathway forward for marketing authorization.

Aeolian Advisors uses information, reports, and data from various sources, but the investment recommendations are based primarily on Aeolian Advisors’ own internal research and analyses, and the experience of Aeolian Advisors’ key personnel. Research information or specialty technical and scientific assessments from third parties may be used.

Small and emerging growth companies are often pre-revenue; spending corporate funds on the discovery and development of new pharmaceutical agents or medical devices. That means traditional financial models of valuation are often less useful in the provision of advice regarding specific recommended investments. The investment strategy for a specific client is based upon the objectives stated by the client during consultations.